Cassava Sciences shifts to epilepsy drug development after Alzheimer’s setback. Learn why insider buys sparked a stock surge but risks remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback